Fig. 6: Combined inhibition of SIK1 and CHEK1 shows enhanced efficacy in DSRCT cells.
From: Salt-Inducible Kinase 1 is a potential therapeutic target in Desmoplastic Small Round Cell Tumor
Dose-response curves of JN-DSRCT-1, BER-DSRCT, and LP9 cells treated with A YKL-05–099 alone or B in combination with 0.5 nM prexasertib and increasing doses of YKL-05–099. DSRCT cell viability values were compared to LP9 cell viability at each dose (*p < 0.05, **p < 0.01, ***p < 0.001, mean ± SEM, student t-test). C IC50 values for YKL-05–099, prexasertib, or combination treatement (0.5 nM prexasertib with increasing doses of YKL-05–099).
